The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML

NCT02204644 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

CML, CML-CP,MMR,TKI

Interventions

DRUG: Flumatinib 600mg qd
DRUG: Imatinib 400mg qd

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.